Changes in US stocks | Moderna (MRNA.US) fell more than 4% after being downgraded by HSBC
Moderna Analyst Ratings
RBC Capital Reiterates Outperform on Moderna, Maintains $125 Price Target
Canaccord Genuity Maintains Hold on Moderna, Raises Price Target to $91
Moderna Analyst Ratings
TD Cowen Maintains Market Perform Rating on Moderna Amid RSV Vaccine Concerns
Critical Insights From Moderna Analyst Ratings: What You Need To Know
RBC Capital Reiterates Outperform on Moderna, Maintains $125 Price Target
Moderna Analyst Ratings
Changes in US stocks | Moderna (MRNA.US) reversed the market and rose more than 10% to receive Oppenheimer's rating
Oppenheimer Lifts Moderna Rating on Key 2024/2025 Catalysts
Moderna Analyst Ratings
Morgan Stanley Cuts Price Target on Moderna to $92 From $115, Keeps Equalweight Rating
Moderna Analyst Ratings
JPMorgan Adjusts Moderna Price Target to $90 From $93, Maintains Neutral Rating
Canaccord Genuity Initiates Coverage On Moderna With Hold Rating, Announces Price Target of $82
Moderna Analyst Ratings
UBS Lowers Moderna's Price Target to $143 From $178, Keeps Buy Rating
Moderna Analyst Ratings
Goldman Sachs Maintains Buy on Moderna, Lowers Price Target to $231
No Data